The UK Competition Authority imposes a fine of £260M on hydrocortisone suppliers for charging excessive and unfair prices to the National Health Service (Auden Mckenzie / Actavis)

KEYWORDS
Reference

UK Competition Authority, Auden Mckenzie / Actavis, Press release, 15 July 2021

On 15 July 2021, the CMA imposed fines of more than £260 million on the hydrocortisone tablet suppliers, Auden Mckenzie and Actavis (now named Accord-UK), for charging excessive and unfair prices and for paying potential rivals to remain out of the market (see CMA Press Release). CMA Chief Executive, Andrea Coscelli, referred to the CMA’s findings as “without doubt some of the most

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.